Get the Stockscreener App
186.05
1.40%
2.56
After Hours:
186.05
Icon Plc stock is traded at $186.05, with a volume of 803.56K.
It is up +1.40% in the last 24 hours and up +6.31% over the past month.
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
See More
Previous Close:
$183.49
Open:
$183.56
24h Volume:
803.56K
Relative Volume:
0.67
Market Cap:
$15.02B
Revenue:
$8.19B
Net Income/Loss:
$758.19M
P/E Ratio:
20.27
EPS:
9.18
Net Cash Flow:
$1.06B
1W Performance:
-2.30%
1M Performance:
+6.31%
6M Performance:
+29.17%
1Y Performance:
-37.28%
1-Day Range:
$182.29
$188.18
1-Week Range:
$181.09
$192.74
52-Week Range:
$125.10
$301.45
Icon Plc Stock (ICLR) Company Profile
Compare ICLR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
186.05 | 14.27B | 8.19B | 758.19M | 1.06B | 9.18 |
|
TMO
Thermo Fisher Scientific Inc
|
524.58 | 198.17B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
205.14 | 144.97B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
633.32 | 49.29B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
138.23 | 38.73B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
203.77 | 33.69B | 15.70B | 1.24B | 2.01B | 6.9036 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-25 | Downgrade | Jefferies | Buy → Hold |
| Sep-03-25 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Aug-21-25 | Downgrade | Citigroup | Buy → Neutral |
| Jul-24-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-29-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-14-25 | Downgrade | TD Cowen | Buy → Hold |
| Apr-10-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Jan-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-14-24 | Initiated | Redburn Atlantic | Neutral |
| Sep-18-24 | Initiated | Leerink Partners | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| Dec-15-23 | Initiated | Truist | Buy |
| Sep-13-23 | Initiated | TD Cowen | Outperform |
| Jan-17-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Jan-13-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-09-22 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-07-22 | Initiated | UBS | Buy |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-12-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Sep-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-23-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-21 | Initiated | Citigroup | Neutral |
| Apr-13-21 | Resumed | BofA Securities | Neutral |
| Apr-01-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-03-21 | Initiated | Barclays | Equal Weight |
| Mar-01-21 | Upgrade | UBS | Neutral → Buy |
| Feb-26-21 | Upgrade | Truist | Hold → Buy |
| Jul-24-20 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-20-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Hold |
| Jan-27-20 | Downgrade | SunTrust | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Sep-23-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jul-26-19 | Upgrade | UBS | Sell → Neutral |
| Jan-25-19 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-09-18 | Initiated | UBS | Sell |
| Apr-03-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-18 | Reiterated | Mizuho | Neutral |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
| Oct-27-17 | Reiterated | Barclays | Equal Weight |
| Sep-11-17 | Initiated | BofA/Merrill | Buy |
| Jul-31-17 | Upgrade | SunTrust | Hold → Buy |
| Jul-27-17 | Reiterated | Mizuho | Neutral |
| Jun-29-17 | Upgrade | Jefferies | Hold → Buy |
View All
Icon Plc Stock (ICLR) Latest News
Inspire Investing LLC Raises Holdings in Icon Plc $ICLR - MarketBeat
ICON plc (ICLR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
L. Roy Papp & Associates LLP Reduces Holdings in Icon Plc $ICLR - MarketBeat
Evercore Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $240 - 富途牛牛
ICON plc Experiences Valuation Adjustment Amidst Competitive Market Landscape - Markets Mojo
Running Oak Capital LLC Has $15.60 Million Holdings in Icon Plc $ICLR - MarketBeat
Sendero Wealth Management LLC Buys New Stake in Icon Plc $ICLR - MarketBeat
Icon Plc $ICLR Stock Position Increased by Marks Group Wealth Management Inc - MarketBeat
ICON plc Announces Third Quarter 2025 Earnings Call - MSN
AstraZeneca and Icon Plc Launch Eplontersen Safety Study for Pregnant and Lactating Individuals - TipRanks
What Analysts Are Saying About Icon Stock - Benzinga
ICON suspends COVID vaccine study after BARDA notice - MSN
Can ICON’s Rebound Sustain Momentum? - StocksToTrade
ICON plc Hits Day High with 7.67% Surge in Strong Intraday Performance - Markets Mojo
Real World Evidence Solutions Research and Forecast Report 2025-2030: Growth Opportunities in Emerging Markets and Increased Focus on End-To-End Rwe Services, & Personalized and Precision Medicine - GlobeNewswire Inc.
Is ICON plc’s Stock Soaring for the Right Reasons? - StocksToTrade
ICON plc Forms Golden Cross, Signaling Potential Bullish Breakout Ahead - Markets Mojo
ICON plc (ICLR): Revolutionizing Clinical Trials with AI Innovations - MSN
ICON plc (ICLR) Stock Analysis: An Investor’s Guide to Understanding Its 31.67% Upside Potential - DirectorsTalk Interviews
ICON plc Schedules Third Quarter 2025 Earnings Conference Call - PharmiWeb.com
ICON plc Schedules Third Quarter 2025 Earnings Conference Call | User | sweetwaterreporter.com - FinancialContent
Canoe Financial LP Increases Position in Icon Plc $ICLR - MarketBeat
ICON Properties Plc (Malawi) | Interim Dividend Notice - AfricanFinancials
Farmers & Merchants Investments Inc. Purchases 2,181 Shares of Icon Plc $ICLR - MarketBeat
Icon Plc $ICLR Shares Sold by Swedbank AB - MarketBeat
Financiere des Professionnels Fonds d investissement inc. Purchases 11,894 Shares of Icon Plc $ICLR - MarketBeat
Goldman Sachs Group Inc. Sells 106,606 Shares of Icon Plc $ICLR - MarketBeat
Greenhaven Associates Inc. Takes Position in Icon Plc $ICLR - MarketBeat
LVM Capital Management Ltd. MI Sells 16,096 Shares of Icon Plc $ICLR - MarketBeat
U.S. Contract Research Organization Market Set for Dynamic Expansion as Key Players like IQVIA INC., ICON plc, Labcorp, Syneos Health - industrytoday.co.uk
Mizuho Securities Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $225 - 富途牛牛
Did ICON’s (ICLR) Internal CEO Succession Signal Strategic Continuity or Missed Opportunity for Change? - simplywall.st
Jefferies rates IQVIA, Charles River as Buy, ICON as Hold - MSN
Brokerages Set Icon Plc (NASDAQ:ICLR) PT at $219.64 - MarketBeat
Jefferies Downgrades ICON Public Limited (ICLR) to Hold From Buy - Insider Monkey
TD Cowen Maintains Icon PLC(ICLR.US) With Hold Rating, Cuts Target Price to $183 - 富途牛牛
Baird Financial Group Inc. Cuts Holdings in Icon Plc $ICLR - MarketBeat
ICON plc (ICLR): Assessing Valuation as CEO Transition Confirms Stability and 2025 Guidance - simplywall.st
Icon Plc Stock (ICLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):